

# Alessandro Loglio

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/1447994/alessandro-loglio-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

31  
papers

732  
citations

11  
h-index

26  
g-index

60  
ext. papers

1,030  
ext. citations

4  
avg, IF

3.79  
L-index

#	Paper	IF	Citations
31	Incremental value of HBcrAg to classify 1582 HBeAg-negative individuals in chronic infection without liver disease or hepatitis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 53, 733-744	6.1	2
30	Safety and effectiveness of up to 3 years bulevirtide monotherapy in patients with HDV-related cirrhosis. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	3
29	Predictive performance of newer Asian hepatocellular carcinoma risk scores in treated Caucasians with chronic hepatitis B. <i>JHEP Reports</i> , <b>2021</b> , 3, 100290	10.3	0
28	Circulating cell-free DNA species affect the risk of hepatocellular carcinoma in treated chronic hepatitis B patients. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 464-474	3.4	1
27	Functional reconstitution of HBV-specific CD8 T cells by in vitro polyphenol treatment in chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 783-793	13.4	9
26	Novel Therapies That May Cure Chronic Hepatitis B Virus. <i>Clinics in Liver Disease</i> , <b>2021</b> , 25, 875-899	4.6	0
25	Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 1037-1045	13.4	34
24	Hepatocellular carcinoma prediction beyond year 5 of oral therapy in a large cohort of Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1088-1096	13.4	50
23	Quadruple mutation GCAC1809-1812TTCT acts as a biomarker in healthy European HBV carriers. <i>JCI Insight</i> , <b>2020</b> , 5,	9.9	2
22	Hepatitis Delta Virus Acts as an Immunogenic Adjuvant in Hepatitis B Virus-Infected Hepatocytes. <i>Cell Reports Medicine</i> , <b>2020</b> , 1, 100060	18	10
21	Application of EASL 2017 criteria for switching hepatitis B patients from tenofovir disoproxil to entecavir or tenofovir alafenamide. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1164-1169	3.3	6
20	The combination of PIVKA-II and AFP improves the detection accuracy for HCC in HBV caucasian cirrhotics on long-term oral therapy. <i>Liver International</i> , <b>2020</b> , 40, 1987-1996	7.9	18
19	Genome-wide Association Study Identifies Genetic Variants Associated With Early and Sustained Response to (Pegylated) Interferon in Chronic Hepatitis B Patients: The GIANT-B Study. <i>Clinical Infectious Diseases</i> , <b>2019</b> , 69, 1969-1979	11.6	7
18	SAT-130-Incidence and outcome of portal vein thrombosis in 817 HBV and HCV compensated cirrhotic patients under antiviral treatment: a single center longitudinal study. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e687-e688	13.4	2
17	Minimal increases of serum alpha-foetoprotein herald HCC detection in Caucasian HBV cirrhotic patients under long-term oral therapy. <i>Liver International</i> , <b>2019</b> , 39, 1964-1974	7.9	7
16	Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 834-839	13.4	30
15	Lamivudine prophylaxis prevents hepatitis B virus reactivation in anti-HBc positive patients under rituximab for non-Hodgkin lymphoma. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 419-424	3.3	4

14	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , <b>2019</b> , 39, 484-493	7.9	8
13	Serum hepatitis B core-related antigen (HBcrAg) correlates with covalently closed circular DNA transcriptional activity in chronic hepatitis B patients. <i>Journal of Hepatology</i> , <b>2019</b> , 70, 615-625	13.4	117
12	Tenofovir alafenamide (TAF) treatment of HBV, what are the unanswered questions?. <i>Expert Review of Anti-Infective Therapy</i> , <b>2018</b> , 16, 153-161	5.5	11
11	Eight-year survival in chronic hepatitis B patients under long-term entecavir or tenofovir therapy is similar to the general population. <i>Journal of Hepatology</i> , <b>2018</b> , 68, 1129-1136	13.4	64
10	Treatment of hepatitis B: Is there still a role for interferon?. <i>Liver International</i> , <b>2018</b> , 38 Suppl 1, 79-83	7.9	23
9	IFNL4 rs368234815 and rs117648444 variants predict off-treatment HBsAg seroclearance in IFN-treated HBeAg-negative chronic hepatitis B patients. <i>Liver International</i> , <b>2018</b> , 38, 417-423	7.9	7
8	Long-term Outcomes in Patients with HBV Treated with Antiviral Agents. <i>Current Hepatology Reports</i> , <b>2018</b> , 17, 502-510	1	1
7	Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 431-439	6.1	6
6	A STAT4 variant increases liver fibrosis risk in Caucasian patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2018</b> , 48, 564-573	6.1	8
5	Hepatitis B virus long-term impact of antiviral therapy nucleot(s)ide analogues (NUCs). <i>Liver International</i> , <b>2017</b> , 37 Suppl 1, 45-51	7.9	37
4	The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B. <i>Hepatology</i> , <b>2017</b> , 66, 1444-1453	11.2	180
3	Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. <i>Journal of Hepatology</i> , <b>2017</b> ,	13.4	15
2	Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: two case reports. <i>Haematologica</i> , <b>2017</b> , 102, e423-e426	6.6	5
1	The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 1118-25	13.4	56